Goldman Sachs Starts Acadia Pharmaceuticals (ACAD) at Neutral

November 11, 2016 8:06 AM EST
Get Alerts ACAD Hot Sheet
Price: $31.95 -1.11%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade ACAD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Goldman Sachs initiated coverage on Acadia Pharmaceuticals (NASDAQ: ACAD) with a Neutral rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $29.74 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Goldman Sachs

Add Your Comment